மும்மடங்கு சிகிச்சை News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Triplet’s New Huntington Disease Drug May Also Treat Other Repeat Expansion Disorders Source: Pixabay April 28, 2021 In a virtual presentation at the CHDI Foundation’s 16 th Annual Huntington’s Disease (HD) Therapeutics Conference, Triplet Therapeutics presented preclinical data on the therapeutic target and route of administration of its first clinical candidate, an antisense oligonucleotide, TTX-3360. This is the first therapeutic candidate with the potential to modify the course of HD and other repeat expansion disorders (REDs). Triplet Therapeutics also pledged to place 1% of its equity into an independently managed trust fund that will monetize the equity to benefit RED patients and their families. “I think this is really important. It’s the first time this has ever been done in the biotech industry. I hope the industry looks at this and uses it as a template across other indications,” said Nessan Bermingham, PhD, Triplet Therapeutics CEO, pre

Irina antonijevicZofia miedzybrodzkaNessan berminghamInstitute of medical sciencesUniversity of aberdeenAnnual huntingtonTherapeutics conferenceTriplet therapeuticsMedical geneticsMedical sciencesநிறுவனம் ஆஃப் மருத்துவ அறிவியல்பல்கலைக்கழகம் ஆஃப் குட்டைநாய் வகைஆண்டு ஹண்டிங்டன்சிகிச்சை மாநாடுமும்மடங்கு சிகிச்சைமருத்துவ ஜெநெடிக்ஸ்